Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial

References

• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Hib and pneumococcal global burden of disease study team; Hib and pneumococcal global burden of disease study team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374(9693):893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Schrag SJ, Beall B, Dowell SF. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000; 13:588-601; PMID:11023959; http://dx.doi.org/10.1128/CMR.13.4.588-601.2000
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24; PMID:11136262; http://dx.doi.org/10.1056/NEJM200012283432603
   PubMed Web of Science ®Google Scholar
• McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9:424-30; PMID:12627227; http://dx.doi.org/10.1038/nm839
   PubMed Web of Science ®Google Scholar
• Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54; PMID:14998500; http://dx.doi.org/10.1016/S1473-3099(04)00938-7
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93; PMID:15680778; http://dx.doi.org/10.1016/S1473-3099(05)01280-6
   PubMed Web of Science ®Google Scholar
• Type Study Group for Pneumococcus. Serotype study for Streptococcus pneumonia in 18 provinces, China. Chin J Epidemiol 1989; 10(3):133-7. [in Chinese]; PMID:2673527
   PubMedGoogle Scholar
• Yao KH, Yang YH. Streptococcus pneumoniae diseases in Chinese children: past, present and future. Vaccine 2008; 26:4425-33; PMID:18602435; http://dx.doi.org/10.1016/j.vaccine.2008.06.052
   PubMed Web of Science ®Google Scholar
• Zhao GM, Black S, Shinefield H, Wang CQ, Zhang YH, Lin YZ, Lu JL, Guo YF, Jiang QW. Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China [J]. Pediatr Infect Dis J 2003; 22:739-42; PMID:12913778; http://dx.doi.org/10.1097/01.inf.0000078373.54515.40
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, Wang H, Zhang H, Wang L, Chu Y, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 2008; 61:256-63; PMID:18358662; http://dx.doi.org/10.1016/j.diagmicrobio.2008.02.004
   PubMed Web of Science ®Google Scholar
• Xue L, Yao K, Xie G, Zheng Y, Wang C, Shang Y, Wang H, Wan L, Liu L, Li C, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumonia isolates that cause invasive disease among Chinese children. Clinical Infect Dis 2010; 50:741-4; http://dx.doi.org/10.1086/650534
   PubMed Web of Science ®Google Scholar
• Zhou L, Ma X, Gao W, Yao KH, Shen AD, Yu SJ, Yang YH. Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010. BMC Microbiol 2012; 12:228; PMID:23043378; http://dx.doi.org/10.1186/1471-2180-12-228
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao R, Ma Z, Yao K, Yu S, Zheng Y, Yang Y. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children's Hospital. PLoS One 2013; 8(6):e67507; PMID:23840728; http://dx.doi.org/10.1371/journal.pone.0067507
   PubMed Web of Science ®Google Scholar
• Zhao C, Zhang F, Chu Y, Liu Y, Cao B, Chen M, Yu Y, Liao K, Zhang L, Sun Z, et al. Phenotypic and genotypic characteristic of invasive Pneumococcal isolates from both children and adult patients from a multicenter surveillance in China 2005–2011. PLoS One 2013; 8(12):e82361; PMID:24349263; http://dx.doi.org/10.1371/journal.pone.0082361
   PubMed Web of Science ®Google Scholar
• Zhou L, Yu SJ, Gao W, Yao KH, Shen AD, Yang YH. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011; (29):7704-10; PMID:21839135; http://dx.doi.org/10.1016/j.vaccine.2011.07.137
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Active bacterial core surveillance of the emerging infections program network. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, et al. Active bacterial core surveillance of the emerging infections program network. Effect of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63; PMID:16598044; http://dx.doi.org/10.1056/NEJMoa051642
   PubMed Web of Science ®Google Scholar
• Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, Goldstein R, Huot H, Finkelstein JA. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumonia carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007; 195:347-52; PMID:17205472; http://dx.doi.org/10.1086/510249
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Active bacterial core surveillance team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49(2):e23-9; PMID:19522653; http://dx.doi.org/10.1086/600045
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/NEJMoa1209165
   PubMed Web of Science ®Google Scholar
• Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15(Suppl 3):16-20; PMID:19366365; http://dx.doi.org/10.1111/j.1469-0691.2009.02726.x
   PubMed Web of Science ®Google Scholar
• Burgos J, Falcó V, Borrego A, Sordé R, Larrosa MN, Martinez X, Planes AM, Sánchez A, Palomar M, Rello J, et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013; 1:385-91; PMID:22583156; http://dx.doi.org/10.1111/j.1469-0691.2012.03895.x
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 21:1453-60; PMID:1944423; http://dx.doi.org/10.1056/NEJM199111213252101
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8; PMID:12560191; http://dx.doi.org/10.1016/S1473-3099(03)00514-0
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine 2009; 27:1504-10; PMID:19171174; http://dx.doi.org/10.1016/j.vaccine.2009.01.013
   PubMed Web of Science ®Google Scholar
• Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010; 51(1):15-22; PMID:20504233; http://dx.doi.org/10.1086/653114
   PubMed Web of Science ®Google Scholar
• Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22:3214-24; PMID:15297076; http://dx.doi.org/10.1016/j.vaccine.2003.08.050
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/NEJMoa022678
   PubMed Web of Science ®Google Scholar
• Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C. EVAN Study Group. Protective effects of the 23-Valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8; PMID:16941367; http://dx.doi.org/10.1086/507340
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-23; PMID:18444818; http://dx.doi.org/10.1086/529142
   PubMed Web of Science ®Google Scholar
• Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, Aliberti S, Blasi F, Fernandez-Gonzalez R, Lopardo G, et al. CAPO Investigators. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumonia community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014; 32:2198-203; PMID:24613522; http://dx.doi.org/10.1016/j.vaccine.2014.02.048
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-8):1-24; PMID:9132580
   PubMedGoogle Scholar
• Centers for Disease Control Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:102-106; PMID:20134399
   PubMedGoogle Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Active bacterial core surveillance team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; (1):CD000422; PMID:18253977
   PubMedGoogle Scholar
• Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42(April 15):1093-101; PMID:16575726; http://dx.doi.org/10.1086/501354
   PubMed Web of Science ®Google Scholar
• Macintyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI. A randomized clinical trial of the immunogenicity of 7-Valent pneumococcal conjugate vaccine compared to 23-Valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014 Apr 23; 9(4):e94578; PMID:24760002; http://dx.doi.org/10.1371/journal.pone.0094578
   PubMedGoogle Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013 Aug 2; 31(35):3594-602; PMID:23688525; http://dx.doi.org/10.1016/j.vaccine.2013.04.084
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013 Aug 2; 31(35):3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
   PubMed Web of Science ®Google Scholar
• Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201(4):516-24; PMID:20092407; http://dx.doi.org/10.1086/649839
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged >65 years. J Infect Dis 2010; 201(4):525-33; PMID:20088694; http://dx.doi.org/10.1086/651131
   PubMed Web of Science ®Google Scholar
• Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010; 201:659-61; PMID:20113178; http://dx.doi.org/10.1086/651376
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198(October 1):1019-27; PMID:18710324; http://dx.doi.org/10.1086/591629
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52(6):736-42; PMID:21367726; http://dx.doi.org/10.1093/cid/cir003
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25(20):4029-37; PMID:17391816; http://dx.doi.org/10.1016/j.vaccine.2007.02.062
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis 2009; 49(9):1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7(9):597-606; PMID:17714673; http://dx.doi.org/10.1016/S1473-3099(07)70210-4
   PubMed Web of Science ®Google Scholar